This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: November 24th, 2008 - November 24th, 2009
This activity is no longer available for credit, however its content is still relevant for your educational needs.
This educational publication is designed for physicians, nurses, and pharmacists who wish to enhance their knowledge concerning the management of side effects associated with multiple myeloma therapy.
At the completion of this activity participants should be able to:
- Summarize the most common side effects associated with novel agents used in the treatment of multiple myeloma (MM)
- Identify the side effects associated with these agents in various combination regimens
- Discuss appropriate management strategies for MM patients experiencing treatment-related side effects and disease-related complications
In direct response to the September 2004 ACCME Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to the date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during the CME/CE activity. The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA-approved uses of pharmaceutical, medical equipment, prostheses, etc will be included in their presentation.
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.
Lillian Chou, PharmD has nothing to disclose.
Charise Gleason, MSN, ANP-BC, AOCNP, is a consultant for Merck and Millennium.
Cindy Ippoliti, PharmD, is on the speakerâ€™s bureau for Eisai and Schering-Plough.
Lisa Smith, MSN, FNP, AOCN is a speaker for Celgene, Medtronic, Millennium, and Novartis.
*Content will include non-FDA-approved uses.
The contents of some CME activities may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.